Ozempic and Opioids (Oxycodone, Hydrocodone, Tramadol): Drug Interaction Guide

Ozempic contains semaglutide, a GLP-1 receptor agonist administered by injection and approved by the FDA to treat type 2 diabetes (Wegovy delivers the same active ingredient in higher doses for weight management, while Rybelsus offers an oral tablet form with distinct absorption characteristics). The following review examines how semaglutide injections interact with three widely used oral opioid pain relievers: oxycodone, hydrocodone, and tramadol.

The direct answer: Ozempic (semaglutide) can be taken with oxycodone, hydrocodone, or tramadol; no FDA labeling or major interaction database lists this combination as contraindicated. Both drug classes slow gastric motility through separate mechanisms, so a patient escalating semaglutide dose while on a new oral opioid may notice slower or less predictable onset of pain relief and a higher combined burden of nausea and constipation. As of 2026, no published randomized trial has directly measured semaglutide's effect on oxycodone, hydrocodone, or tramadol pharmacokinetics in humans, so the absorption-timing effect is plausible and mechanistically grounded but not independently confirmed for this specific opioid group.

Why this combination comes up so often

Semaglutide prescribing has grown rapidly for both diabetes and weight management, and opioid analgesics remain widely prescribed for acute and chronic pain in the United States. National dispensing surveillance from the CDC tracks opioid prescribing rates by state and over time (CDC opioid dispensing data), confirming that opioid use remains common even as rates have declined from their peak. The overlap population, patients on a GLP-1 receptor agonist who are also prescribed an oral opioid, is not small, which is why the interaction question comes up regularly in pharmacy and primary care settings even though it has not been the subject of a dedicated trial.

The mechanism: two drugs slowing the same process

Semaglutide activates GLP-1 receptors in the enteric nervous system and vagal afferents, which slows gastric emptying. This is a labeled, dose-dependent effect and is most pronounced in the weeks following each dose increase. The Ozempic prescribing information states that semaglutide delays gastric emptying and can affect absorption of concomitantly administered oral drugs (FDA-approved Ozempic label).

Opioids independently reduce gastrointestinal motility through mu-opioid receptor activation in the myenteric plexus, a mechanism well established in the pain and gastroenterology literature and reflected in FDA labeling for opioid analgesics generally.

When both mechanisms are active, gastric transit time may extend further than either drug alone would produce. For an oral opioid, this could mean a later-than-usual peak blood concentration, which matters most in two situations: a patient assumes the medication "isn't working" and takes an early repeat dose, or a delayed bolus of drug empties into the intestine at once and produces a sharper absorption spike than expected. This absorption-shift concern is extrapolated from the known pharmacology of gastric emptying and from PK studies GLP-1 manufacturers have run with other oral drugs; it has not been demonstrated in a controlled study using oxycodone, hydrocodone, or tramadol specifically, and any precise numeric claim about how much the timing shifts for these particular opioids should be treated as unverified until a primary source is checked.

Semaglutide does not meaningfully inhibit or induce CYP450 enzymes. Oxycodone is metabolized substantially through CYP3A4, hydrocodone is converted to hydromorphone via CYP2D6, and tramadol depends on CYP2D6 to form its active metabolite. Because semaglutide does not interfere with these pathways, the hepatic metabolism of these opioids is not expected to change. The interaction, to the extent it exists, is a gastrointestinal transit issue, not a liver enzyme issue.

Overlapping side effects: the part that is better documented

Nausea is the most commonly reported adverse effect of semaglutide across its labeled dosing range, and its incidence rises with dose according to the FDA label. Nausea and constipation are also long-recognized opioid side effects, driven by direct effects on the chemoreceptor trigger zone and gut motility respectively. Combining the two drug classes plausibly raises the total burden of nausea and constipation compared with either drug alone, though the specific combined incidence in patients taking both together has not been reported in the material reviewed for this article and should not be quoted as a precise figure without checking a primary source.

Constipation from opioids is a recognized clinical problem addressed by standard laxative-first management strategies, escalating to peripherally acting mu-opioid receptor antagonists (PAMORAs) such as naloxegol or methylnaltrexone for refractory cases when a clinician has assessed the patient. Patients on both semaglutide and a chronic opioid should be screened for constipation at routine visits rather than waiting for a symptom report.

Tramadol specifically

Tramadol differs from oxycodone and hydrocodone because it also inhibits serotonin and norepinephrine reuptake and carries a labeled, dose-dependent seizure risk. Semaglutide has no known serotonergic activity, so there is no established mechanism for serotonin syndrome from this pairing. A seizure-threshold interaction between semaglutide and tramadol is mechanistically conceivable if unpredictable absorption produced erratic plasma levels, but no published case series or signal specific to this combination was identified in the sources reviewed here. This should be treated as a theoretical awareness point for patients with existing seizure risk factors, not an established interaction.

Evidence-status assessment: what is known, plausible, or unverified

Perioperative considerations

The American Society of Anesthesiologists released 2023 consensus-based guidance addressing preoperative management of patients on GLP-1 receptor agonists, motivated by concern that delayed gastric emptying could increase the risk of residual gastric contents and aspiration during induction of anesthesia (ASA consensus guidance, 2023). Patients taking chronic opioids in addition to semaglutide may have compounded delays in gastric emptying from opioid-related motility effects, which makes disclosure of both medications to the surgical and anesthesia team important well before a scheduled procedure. Specific numeric findings about how much more often residual gastric contents are seen in GLP-1 users, reported in some observational studies, should be verified against the primary publication before being cited as a fixed rate, since exact effect sizes vary across the available literature.

Special populations

Chronic non-cancer pain on a stable opioid regimen. This is likely the largest overlap group. A reasonable approach is a pain-control check-in at each semaglutide dose escalation step, distinguishing "the opioid feels delayed" from "the opioid is not working," since the appropriate response differs (adjust timing versus reassess the regimen with the prescriber).

Opioid use disorder treated with buprenorphine or methadone. Sublingual buprenorphine absorption does not depend on gastric emptying, so this specific concern does not apply. Oral methadone could theoretically be affected by delayed gastric transit, but its long and variable half-life and once-daily dosing make a clinically meaningful shift at steady state unlikely; this has not been specifically studied with semaglutide and should be confirmed with the prescribing clinician if a concern arises.

Renal impairment. Semaglutide labeling notes limited experience in advanced renal impairment and recommends monitoring renal function if a patient develops significant GI side effects, since dehydration from nausea or vomiting can affect kidney function. This is a general labeling caution, not a specific opioid interaction finding.

What should prompt urgent care

Severe, persistent vomiting, signs of bowel obstruction (severe abdominal pain, distension, inability to pass gas or stool), excessive sedation or slowed breathing, or a seizure in a patient on tramadol all warrant urgent medical evaluation rather than waiting for a routine follow-up. These are general safety signs for opioid therapy and for severe GI side effects of semaglutide, not evidence of a specific combined syndrome unique to this drug pair.

Practical monitoring approach

No dose adjustment of either semaglutide or the opioid is mandated by current guidelines simply because the two are combined. A reasonable practical approach:

• Reassess pain control and GI symptoms at each semaglutide dose step, not just at the first prescription.
• Counsel patients not to take an early repeat opioid dose because relief "feels delayed"; check with the prescriber instead.
• Screen for constipation proactively rather than waiting for the patient to report it.
• Use one pharmacy for both medications so interaction and duplicate-therapy screening happens automatically.
• Disclose GLP-1 receptor agonist use to any surgical or anesthesia team before a scheduled procedure.

Evidence boundary

Established: semaglutide delays gastric emptying; opioids independently slow gut motility; semaglutide does not meaningfully affect the CYP450 enzymes that metabolize oxycodone, hydrocodone, or tramadol; no absolute contraindication exists in current FDA labeling; the ASA has issued perioperative guidance addressing GLP-1 receptor agonists generally.

Plausible but not directly proven for this opioid group: that combined gastric slowing meaningfully delays or reshapes oral opioid absorption in a clinically important way, and that this effect is strongest during dose titration and attenuates at steady state.

Not established: a confirmed seizure-threshold interaction between tramadol and semaglutide; a distinct adverse-event signal for this drug combination in post-marketing surveillance; any precise numeric rate of additive nausea, constipation, or absorption delay specific to semaglutide plus oxycodone, hydrocodone, or tramadol.

This article does not provide individualized dosing guidance. Opioid and GLP-1 dosing decisions should be made by the prescribing clinician based on the individual patient's pain condition, renal and hepatic function, and overall regimen.